Current optimization of combined therapy for chronic obstructive pulmonary disease
Testing the new combined bronchodilator Anoro Ellipta in different clinical trials gives proof to its high clinical efficacy and safety in chronic obstructive pulmonary disease. The drug contains the molecules of a sustained-release selective β2-adrenergic receptor agonist (vilanterol) and a muscari...
Main Author: | E N Popova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
"Consilium Medicum" Publishing house
2015-12-01
|
Series: | Терапевтический архив |
Subjects: | |
Online Access: | https://ter-arkhiv.ru/0040-3660/article/view/31891 |
Similar Items
-
Clinical experience of using double bronchodilation therapy in patients with COPD
by: I. V. Demko, et al.
Published: (2019-12-01) -
Spotlight on fluticasone furoate/umeclidinium/vilanterol in COPD: design, development, and potential place in therapy
by: Lal C, et al.
Published: (2016-12-01) -
Experience of using double bronchodilation therapy in patients with COPD
by: I. V. Demko, et al.
Published: (2021-01-01) -
Umeclidinium/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week study
by: Kerwin EM, et al.
Published: (2017-02-01) -
Patient perspectives on fluticasone–vilanterol versus other corticosteroid combination products for the treatment of asthma
by: Bollmeier SG, et al.
Published: (2016-05-01)